HTR1A
5-hydroxytryptamine receptor 1A
As of the edition of 20 October 2026, HTR1A (5-hydroxytryptamine receptor 1A, UniProt P08908) has 21 drugs tested at it and 27 companies on the list, 10 on route A and 9 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08908
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 30
- Disease areas
- Mental health; Nervous system; Chemically induced; Nutrition and metabolism; Inherited and neonatal; Digestive system; Hormones; Cancer
- Registered trials of its drugs
- 586
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 10 |
| Went quiet | 4 |
| Stopped | 6 |
| Status not established | 1 |
| Total | 21 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Aripiprazole | Marketed | Phase 4 | none listed |
| Vortioxetine | Marketed | Phase 4 | Ends 2031 |
| Brexpiprazole | Marketed | Phase 4 | Ends 2028 |
| Buspirone | Marketed | Phase 4 | none listed |
| Vilazodone | Marketed | Phase 4 | none listed |
| Flibanserin | Marketed | Phase 4 | Ends 2028 |
| Aripiprazole lauroxil | Marketed | Phase 4 | Ends 2030 |
| Lecozotan | Went quiet | Phase 3 | none listed |
| Pardoprunox | Stopped | Phase 3 | none listed |
| Alverine | Marketed | Phase 4 | none listed |
| Sarizotan | Stopped | Phase 3 | none listed |
| Xaliproden | Stopped | Phase 3 | none listed |
12 of 21 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 10 |
| Route B | 9 |
| Engaged | 2 |
| Undetermined | 6 |
| Total on the list | 27 |
The other 24 companies at HTR1A
In the product27 companies in all; 24 are not named here, and no score is.
See the 27 companies at HTR1A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.